Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Nautilus Biotechnology Inc (NAUT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: NAUT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $1.75
1 Year Target Price $1.75
| 2 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -43.86% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 87.51M USD | Price to earnings Ratio - | 1Y Target Price 1.75 |
Price to earnings Ratio - | 1Y Target Price 1.75 | ||
Volume (30-day avg) 4 | Beta 1.25 | 52 Weeks Range 0.66 - 3.09 | Updated Date 06/30/2025 |
52 Weeks Range 0.66 - 3.09 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.54 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -19.06% | Return on Equity (TTM) -30.93% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -21959808 | Price to Sales(TTM) - |
Enterprise Value -21959808 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2 | Shares Outstanding 126148000 | Shares Floating 46122403 |
Shares Outstanding 126148000 | Shares Floating 46122403 | ||
Percent Insiders 33.38 | Percent Institutions 48.76 |
Analyst Ratings
Rating 2 | Target Price 1.75 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Nautilus Biotechnology Inc
Company Overview
History and Background
Nautilus Biotechnology, Inc. was founded in 2016. It aims to revolutionize proteomics by developing a single-molecule protein analysis platform. Significant milestones include technology development, partnerships, and going public via a SPAC merger.
Core Business Areas
- Proteomics Platform Development: Developing a platform for single-molecule protein analysis to accelerate drug discovery and personalized medicine.
Leadership and Structure
The leadership team consists of experienced scientists and business executives. The organizational structure includes departments for research and development, engineering, and business operations.
Top Products and Market Share
Key Offerings
- Nautilus Proteomic Analysis Platform (In Development): Nautilus is developing a platform aimed at identifying and quantifying proteins at the single-molecule level. Revenue is currently minimal as the platform is pre-commercialization. Competitors include SomaLogic, Olink, and Quanterix. Direct market share is not yet applicable.
Market Dynamics
Industry Overview
The proteomics market is rapidly growing, driven by advancements in technology and increasing demand for personalized medicine and drug discovery. The market is characterized by intense competition and innovation.
Positioning
Nautilus aims to disrupt the proteomics market with its single-molecule analysis platform. Its competitive advantage lies in the potential for higher sensitivity and throughput compared to existing technologies.
Total Addressable Market (TAM)
The proteomics market is projected to reach tens of billions of dollars. Nautilus is positioned to capture a share of this market by providing superior protein analysis capabilities.
Upturn SWOT Analysis
Strengths
- Innovative technology
- Experienced leadership team
- Potential for high sensitivity and throughput
- Strong intellectual property position
Weaknesses
- Pre-commercialization stage
- High research and development costs
- Dependence on successful platform development
- Unproven market adoption
Opportunities
- Partnerships with pharmaceutical companies
- Expansion into new applications
- Increasing demand for personalized medicine
- Potential for market disruption
Threats
- Competition from established players
- Technological advancements by competitors
- Regulatory hurdles
- Funding risks
Competitors and Market Share
Key Competitors
- SOMA
- OLK
- QTRX
Competitive Landscape
Nautilus faces stiff competition from established players in the proteomics market. Its advantage lies in its innovative technology. However, it needs to successfully commercialize its platform to gain market share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is minimal due to the pre-commercialization stage of the company.
Future Projections: Future growth is dependent on the successful development and commercialization of its proteomics platform. Analyst estimates are highly variable and depend on the company's progress.
Recent Initiatives: Recent initiatives include technology development, partnerships, and fundraising activities.
Summary
Nautilus Biotechnology is an early-stage company with innovative proteomics technology. Its success hinges on the successful development and commercialization of its platform. The company faces significant competition and funding risks. However, the potential market opportunity is large and the leadership team is experienced.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, industry reports, analyst estimates.
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nautilus Biotechnology Inc
Exchange NASDAQ | Headquaters Seattle, WA, United States | ||
IPO Launch date 2021-06-10 | Co-Founder, CEO, President, Secretary & Director Mr. Sujal M. Patel | ||
Sector Healthcare | Industry Biotechnology | Full time employees 134 | Website https://www.nautilus.bio |
Full time employees 134 | Website https://www.nautilus.bio | ||
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprising instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent probe binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers reagent kits, which include sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.